A gelatin sponge model of concomitant tumor immunity was employed in order to examine the clonality of T cells associated with progressing and rejected tumor sites. Here we show that freshly isolated T cells bearing TCR V β 1, CDR3 RPGTGN, J β 1.1 and TCR V β 8, CDR3 GD, J β 1.6 predominated progressing and rejected tumor sites. Despite the similarity in T cell populations, the T cells from rejected tumor sites were capable of killing the autologous tumor cells, whereas T cells from progressing tumor sites were not able to do so. The differing cytolytic ability could not be attributed to a difference in TCR ζ chain protein expression levels between both T cell populations. After a 5 day mixed lymphocyte tumor culture the T cells from the progressing tumor site were capable of killing autologous tumor cells, which suggested changes took place within the cell population during in vitro culture. Further TCR analysis revealed T cells bearing TCR V β 1, CDR3 RPGTGN, J β 1.1 and TCR V β 8, CDR3 GD, J β 1.6 were not expanded following the in vitro culture. These data suggest that the lack of cytotoxicity of freshly isolated tumor-infiltrating lymphocytes (TIL) was not due to abnormal TCR ζ chain expression or major differences in the TCR V β usage. Additionally, the gain of TIL effector function did not correlate with an expansion of the TCR bearing T cells found to predominate the in vivo response. These data suggest that the predominant TCR V β used by lymphocytes infiltrating regressing or rejected tumors may not represent the tumor reactive T cells that grow in culture or respond to the autologous tumor in vitro.
Introduction
The absence of palpable tumors following tumor rejection has mediated cytolysis of autologous tumor cells in vitro (3) (4) (5) .
Previously we reported a similarity in the TCR V β usage made it virtually impossible to study the phenotypic and functional characteristics of tumor-infiltrating lymphocytes between the freshly isolated TIL and TRL, and showed IFN-γ, tumor necrosis factor-α and IL-10 were present at greater (TIL) during tumor rejection. Until recently, melanomas undergoing spontaneous regression have provided the best model levels in rejected tumor sites, and transforming growth factor-β was present at greater levels in progressing tumor sites by for studying tumor rejection (1,2). We have employed a gelatin sponge model of concomitant tumor immunity in order to RT-PCR (5) . In this report we examined TIL and TRL for differences in TCR ζ chain levels and the clonality of TCR V β capture T cells associated with rejection of a moderately immunogenic murine mammary carcinoma, EMT6 (3, 4) . This usage of freshly harvested and cultured tumor-associated lymphocytes. model allowed a simultaneous comparison of T lymphocytes infiltrating progressing tumors and tumors undergoing rejecRecently, several laboratories have reported alterations in the protein expression levels of molecules associated with tion in the same host. We demonstrated that whereas TIL from the progressing tumor were not cytolytic, the T cells TCR signaling during progressive tumor growth (6) (7) (8) (9) . Specifically, the TCR ζ chain has been found to be expressed from the rejection site [tumor-rejecting lymphocytes (TRL)] at decreased levels in TIL from several human tumors (7, 8) indicating a successful anti-tumor immune response was initiated. and animal models (6) (7) (8) (9) . Here we report that TIL and TRL showed similar protein expression levels of TCR ζ, and
Isolation of TIL and TRL therefore the lack of cytolytic activity of freshly harvested TIL On day 17 after injection of the primary tumor, animals were could not be attributed to decreased TCR ζ chain protein killed by cervical dislocation. Sponges and tumors were expression. However, TIL acquired effector function after removed, diced and digested in a collagenase cocktail as incubation in an immunostimulatory environment suggesting previously described (3) . The resulting cell suspensions were changes took place during the in vitro culture.
filtered through a 140 µm wire screen and washed with α-MEM The most variable region of the TCR β chain, the CDR3, is buffered with 20 mM morpholinopropane sulfonic acid and involved in antigen binding (10) . An examination of the CDR3 supplemented with 10% FBS (α-10-MOPS). regions in TIL has been performed from several human tumors T lymphocytes were highly enriched from progressing (11) . These data demonstrate the clonality of T cells infiltrating tumors and sponges using the MiniMACS microbeads system progressing tumors and indicate the cells most likely involved (Miltenyi Biotec, Auburn, CA). Tumors and sponges, digested in the anti-tumor immune response. In order to reveal the as previously described (3), were depleted of macrophages clonality of T cells infiltrating progressing and rejected EMT6
by plastic adherence and then passed over a nylon wool tumors we sequenced the CDR3 regions of TIL and TRL. An column to remove additional macrophages and B cells. examination of the freshly isolated TIL and TRL revealed that Approximately 1ϫ10 6 cells were then labeled with 1 µg of rat TCR V β 1, CDR3 RPGTGN, J β 1.1 and TCR V β 8, CDR3 GD, anti-mouse CD11b (Caltag, San Francisco, CA) and 1 µg of J β 1.6 predominated both progressing and rejected tumor rat anti-mouse Gr-1 (PharMingen, San Diego, CA), washed sites. Despite the presence of similar T cell populations, the 1ϫin PBS, and resuspended in 80 µl of PBS. Goat anti-rat TIL lacked tumoricidal activity. In an attempt to expand magnetic microbeads (20 µl, Miltenyi Biotec) were added this population and generate cytotoxic T cells from the TIL and incubated at 4°C for 15 min undisturbed. The cells were population a mixed lymphocyte tumor culture (MLTC) was washed 2ϫin PBS and resuspended in 500 µl PBS. The used. Following the MLTC, the TIL gained cytolytic activity magnetic separation column (Miltenyi Biotec) was prepared and the TRL showed an increase in cytolytic activity toward by running 500 µl of PBS through it. The labeled cells were the autologous tumor. However, the increase in cytolytic then pipetted into the column and allowed to run through. activity in both populations did not correlate with an expansion
The eluent was collected and used as enriched T cells. TRL of the TCR V β 1, CDR3 RPGTGN, J β 1.1 and TCR V β 8, CDR3
were 90% Thy1.2 ϩ and TIL were 70% Thy1.2 ϩ as determined GD, J β 1.1 bearing T cells. These data suggest that the gain by flow cytometric analysis. in TIL effector function and the increase in TRL effector function in vitro did not correlate with an expansion of the T MLTC cells found to predominate the in vivo anti-tumor response.
The T lymphocytes from progressing tumors (TIL) and sponges (TRL) were stimulated in vitro in a MLTC. The TIL and TRL were enriched as described above, and Thousand Oaks, CA) was added at a concentration of The EMT6 tumor cell line used in this study was kindly 40 U/ml in a final volume of 5 ml/well. The low-dose IL-2 was provided by Dr Sara Rockwell (New Haven, CT) and was sufficient for T cell survival, but not for LAK cell generation. maintained in culture as previously described (3). Mice were
The MLTC was then incubated, undisturbed, for 5 days at injected s.c. on the right flank with 1ϫ10 5 viable EMT6 cells 37°C in 7% CO 2 . Non-adherent cells were harvested by in 0.1 ml sterile PBS. Eight days later, tumor-bearing animals vigorous pipeting. were anesthetized with pentobarbital (60 mg/kg body wt), and two 10 mmϫ10 mmϫ10 mm sterile gelatin sponges Cytotoxicity assay (Upjohn, Kalamazoo, MI) were implanted s.c. in the upper
The cytotoxicity of autologous tumor cells by enriched TIL and lower dorsal regions. Separate incisions were made at and TRL was determined in an 8 h 51 Cr-release assay as each implant site to ensure sponge separation throughout previously described (3). Lymphocytes in both TIL and TRL the experiment. Two days following implantation (day 10), populations were equalized based on lymphocyte content the sponges were injected with 1ϫ10 5 EMT6 tumor cells. This after Wright-Giemsa staining. Experiments were performed injection schedule was based on our previous published in triplicate and spontaneous release never exceeded 31%. reports (3, 4) that demonstrated the acquisition of concomitant V β TCR analysis tumor immunity using a challenge time interval of 10 days between the primary and secondary tumor inoculations. By Because antibodies were not available for all of the V β TCR we used RT-PCR to examine V β TCR usage. In order to analyze day 17, no tumor cells can be detected in the sponges, the TCR V β repertoire of TIL and TRL, progressing tumors and sponges were digested with collagenase as described above. Approximately 5ϫ10 6 to 1ϫ10 7 cells from three separate sponge and tumor digests were washed 2ϫin PBS, and poly(A) mRNA and total RNA were isolated using the Invitrogen (San Diego, CA) Micro Fast Track mRNA isolation kit and the Trizol reagent (Life Technologies, Grand Island, NY) respectively. Isolated RNA was routinely treated with DNase (Boehringer Mannheim, Indianapolis, IN) prior to cDNA synthesis. Analysis by PCR, of DNase-treated RNA, did not yield any product (data not shown) confirming an absence of DNA contamination. The resulting RNA was quantified by spectrophotometry and equal amounts of RNA from each source were reverse transcribed using Invitrogen's cDNA Cycle kit. Typically 10-100 ng mRNA or 5 µg total RNA was used per cDNA reaction. The cDNA was then submitted to 
MN) as previously described (5).

CDR3 region analysis
In order to determine the clonality of TIL and TRL, the PCR gelatin type A (Sigma) in TBS] while rocking (Red Rocker; products of the V β which predominated each tumor site were Hoeffer Scientific Instruments, San Francisco, CA). For TCR ligated into the PGEM T vector (Promega, Madison, WI) and ζ analysis, the membranes were incubated with 1 µg/ml of used to transform DH5α Escherichia coli strain (Stratagene anti-mouse CD3 ζ antibody (PharMingen) in 10 ml blocking Cloning Systems, La Jolla, CA). Ampicillin-resistant, white buffer for 2 h while rocking. For CD3ε analysis, the membranes colonies were screened for insert by ApaI-PstI digestion.
were incubated with 1 µg/ml of anti-CD3ε antibody (Dako, Plasmid DNA was then extracted and sequenced using the Carpinteria, CA) in 10 ml blocking buffer for 2 h while rocking. Sequenase version 2.0 DNA sequencing kit (US Biochemical,
The membranes were washed in blocking buffer 2ϫeach for Cleveland, OH). The joining region of the TCR β chain 5 min and incubated with a 1/6000 dilution of goat anti-(J β ) was identified by comparison of these sequences to mouse (TCR ζ) or anti-rabbit (CD3ε) horseradish peroxidase published J β sequences (12) (13) (14) .
conjugate (Sigma) for 45 min. The membranes were washed with TBS 3 times for 5 min each and developed by ECL Western blotting according to the manufacturer's instructions (ECL Western In order to investigate potential differences in the signaling blotting detection reagent; Amersham Life Science, Arlington machinery of the TIL and TRL, Western blots were Heights, IL). performed in order to examine TCR ζ. For these studies the TIL and TRL were purified as described above and equalized for viability by acridine orange/propidium iodine staining Results followed by staining with the Leukostat staining kit (Fisher Cytolytic activity of TIL and TRL Diagnostics, Orangeburg, NY) to determine the percentage of lymphocytes in the samples. Approximately 1ϫ10 6 viable In order to determine if T lymphocytes present in progressing tumors were capable of mediating cytolytic function against lymphocytes were washed 2ϫin PBS containing 1 mM Na 3 VO 4 (Sigma, St Louis, MO) and lysed in 0.15 ml cold lysis autologous tumor cells in vitro, they were re-stimulated in a MLTC. Although unable to lyse tumor cells when initially buffer (20 mM Tris-HCl, pH 8.0, 137 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM NaVO 4 , 2 mM EDTA, 1 mM PMSF, isolated, after 5 days stimulation in vitro, TIL were capable of lysing autologous tumor cells in an 8 h 51 Cr-release assay 1 µg/ml leupeptin, 1 µg/ml aprotinin and 1 µg/ml pepstatin) for 10 min on ice. The lysates were then centrifuged at (Fig. 1 ). Previous published work has shown that the cytolytic activity was not due to NK cell activity (5) . After the MLTC, 10,000 g for 10 min at 4°C. The supernatants were transferred to clean 1.5 ml tubes and an equal volume of 2ϫSDS-PAGE TIL exhibited 25% cytotoxicity at an E:T of 40:1. TRL were cytotoxic towards EMT6 tumor cells prior to (52%) and after buffer (18 ml dH 2 O, 0.12 g Tris base, 1 g SDS, 0.2 ml 0.5 M EDTA, pH 8.0, 0.5 ml 10% sodium azide, 0.1g bromphenol (69%) in vitro stimulation (Fig. 1) . These data indicated that the cytotoxic function of the TIL could be rescued after blue, 5 ml 2-mercaptoethanol and 25 ml glycerol) was added. The samples were stored at -20°C. For protein analysis, the in vitro culture. lysates were heated to 95°C for 5 min and separated on a TCR ζ chain expression 10% SDS-PAGE gel. The protein was transferred to a nylon membrane (Immobilon P; Millipore, Bedford, MA) at 80 V In order to determine if the lack of cytotoxicity by freshly isolated TIL was associated with a decrease in the TCR ζ overnight at 4°C. The membranes were washed 3ϫfor 15 min each in 10 ml of blocking buffer [0.05% Tween 20/1% porcine chain expression we compared TCR ζ chain protein levels in the freshly isolated TIL and TRL (Fig. 2) . Western blot of usage of TCR V β 4, 5.2 and 7 was slightly higher in the TRL than the TIL, these values were not significantly different from analysis revealed that the protein expression levels of TCR ζ their counterparts in spleens from naive non-tumor bearing were similar between the TIL and TRL (Fig. 2) . These data animals (data not shown). The predominance of TCR V β 1 and suggested that the lack of TIL-mediated killing was not 8 bearing T cells in TIL and TRL (Fig. 3A) suggested that related to abnormal TCR ζ chain expression.
these T cell populations may be involved in the in vivo TCR analysis from freshly isolated cells antitumor immune response. Since the differences in cytotoxic activities of TIL and TRL Although TCR V β analysis of the TIL and TRL populations could be due to the presence of different T cell phenotypes, suggested that the same V β families were responding to the these effectors were examined for differences in their TCR V β progressing and rejected tumors, the V β families may have family usage by semi-quantitative PCR. The data revealed a differed within the antigen binding CDR3 region (10) . In order similarity in the TCR Vβ usage by TIL and TRL. The usage of to determine the clonality of the TCR V β , the CDR3 regions TCR V β 1, 8, 10, 11 and 13 was increased in both populations of the most predominant TCR V β in the TIL and TRL were compared to the remaining V β (Fig. 3A) . Although the level sequenced (Table 1 ). In the V β 1 compartment of the progressing and rejected tumors, four of 10 and six of 10 TCRs respectively were J β 1.1 (Table 1) . Three out of the 10 clones sequenced possessed identical diversity regions, CDR3 RPGTGN, associated with J β 1.1 in the progressing tumors and in the rejected tumors (Table 1 ). In the TCR V β 8 compartment, J β 1.6 was utilized in four of 10 TCRs from progressing tumors and in three of 10 TCRs from rejected tumors. The CDR3 sequence of these clones were identical and consisted of a glycine (G) and an aspartic acid (D). compared to the spleens of naïve animals (Table 2) . Similarly, Fig. 3 . TCR V β analysis of TIL and TRL before and after a 5 day MLTC. The TCR V β repertoires of TIL and TRL were examined by RT-PCR before (A) and after (B) a 5 day MLTC. The PCR was performed using TCR V β -specific primers and a common C β primer. The data represent the TCR V β usage from an average of six separate animals prior to MLTC and 10 animals after MLTC.
the V β 8 TCR clones which predominated the EMT6 TIL and the naive spleens (7%) in the 168 tumor system (Table 2) . However, two unique clones predominated the V β 8 TCR TRL (CDR3 GD) were not detected in the spleens of EMT6 tumor bearing animals despite an expansion of the V β 8 TCR bearing T cells in the 168 tumor system (CDR3 SPGR and SEWGGAG) which were not detected in the EMT6 system. bearing T cells in these spleens compared to the spleens of naïve animals (Table 2) . Moreover, the recruitment or expanConversely the V β 8 TCR bearing clones which predominated the EMT6 TIL and TRL (CDR3 GD) were not detected in the sion of these T cells appeared to be tumor dependent. There was no expansion of the V β 1 TCR bearing T cells in a V β 8 TCR bearing clones in the 168 system (Table 2 ). These data emphasize that the TCR bearing T cells recruited to the syngeneic mammary tumor system, 168 ( Table 2) . As in the EMT6 model, the V β 8 TCR bearing T cells were expanded in tumor sites were tumor dependent, clonal in nature and likely involved in the in vivo anti-tumor immune response. the spleens (9%), the TIL (36%) and TRL (68%) compared to TCR analysis after in vitro culture SPGTGN and SQGLGDS) were shared between the TIL and TRL populations after the MLTC, whereas only 1 TCR V β 1 The TCR V β repertoires of TIL and TRL were analyzed after clone (CDR3; RPGTG) was shared between the TIL and in vitro stimulation in order to determine if there was a TRL populations before the MLTC. These findings suggest an preferential expansion of TCR V β 1 and 8 bearing T cells. The increased clonality in the TCR V β 1 TCR compartment during data instead revealed a spreading of TCR V β usage during in vitro stimulation. In the TCR V β 8 compartment, J β 1.6 usage MLTC. Whereas a decrease in TCR V β 1 and 8 usage occurred, predominated both TIL and TRL clones in vivo (Table 1) but an increase in TCR V β 4, 5.1, 5.2, 6, 9, 12 and 15 usage was was absent in cells analyzed after in vitro stimulation (Table 3) . observed (Fig. 3B) . Before in vitro expansion, T cells bearing TCR V β 1 represented 20% of the TIL and 19% of the TRL, and T cells bearing the TCR V β 8 represented 19% of the TIL Discussion and 14% of the TRL (Fig. 3A) . After MLTC, the percent cells bearing TCR V β 1 decreased to 7% in the TIL and 6% in the Most investigations of antitumor immune responses focus on progressing tumors (15-19). Tumor-associated lymphocytes TRL (Fig. 3B) . Similarly, T cells expressing TCR V β 8 dropped to 12% in the TIL and 9% in the TRL (Fig. 3B) . These data from rejected or regressing tumors should provide information on the requirements for an effective antitumor immune suggested that cells expressing TCR other than TCR V β 1 and 8 were expanded during in vitro stimulation and may be response. To date only two studies have examined TIL in a spontaneously rejected human melanoma (1,2). In these involved in antigen recognition in vitro.
One possible explanation for the decrease in V β 1 and 8 studies, the TCR V β usage and clonality of the T cell response was investigated. Whereas TCR V β 16, CDR3 LRDSWN, J β TCR-bearing cells after MLTC is that some clones expressing these receptors did not respond to the EMT6 tumor-associated 2.1 was found to be the most predominant TCR used during the in vivo antitumor immune response (1), TCR V β 13, CDR3 antigens and died, leaving a population of clonally restricted cells. In order to determine whether this occurred, the CDR3 WGGD, J β 1.1 was found to predominate a TIL line and clone grown from the bulk TIL population (2) . These data suggest regions of the TCR V β 1 and 8 bearing T cells were sequenced after MLTC. The CDR3 region analysis of the TCR V β 1 TIL that the predominant TCR bearing T cells in vivo may not be the ones that respond to the tumor in vitro. showed there was an expansion in the usage of J β 1.1 from 40% before the MLTC to 80% following MLTC. Interestingly,
Our well-described model of concomitant tumor immunity (3-5) allows the simultaneous analyses of TCRs involved in the CDR3 sequence (RPGTGN) present in clones analyzed before the MLTC was absent in those sequenced post-MLTC tumor progression and rejection. Using this model we have shown that T cells isolated from progressing tumors were (Table 3) . Overall, three TCR V β 1 TIL clones (CDR3; SPGQGN, non-cytolytic, whereas T cells from rejected tumor sites were maturation of precursor cytotoxic T lymphocytes to cytotoxic T lymphocytes, still resulted in increased cytolytic activity by cytolytic towards the autologous tumor in vitro (3) (4) (5) .
The lack of cytotoxicity by freshly isolated TIL suggested the TIL population (data no shown). These data suggest that cytotoxic T lymphocytes were present in the TIL population that either these cells were impaired or consisted of a T cell population different from TRL. In order to address the first in vivo and only showed tumor cytolysis after in vitro culture. Although we have been able to block 15% of the TRL possibility we examined TCR ζ chain expression. Abnormal TCR ζ chain expression in TIL from melanoma, colon cancer cytotoxicity against the EMT6 tumor cells using a TCR V β 8-specific antibody, we have also found that V β 8 TCR bearing and renal cell carcinoma has been implicated as a factor contributing to progressive tumor growth (6) (7) (8) (9) . It has been T cell clones, grown in culture with repeated tumor cell stimulation, showed no cytolytic activity (data not shown). alluded to in these reports that the abnormal TCR ζ expression may be related to the progressive tumor growth. The gelatin This suggests that the V β 8 TCR bearing T cells, which exhibit cytolytic activity, are not the cells that grow in vitro. Therefore, sponge model of concomitant tumor immunity provided a system to investigate T cells from progressing and rejected the only way to determine which T cells are responding to the tumor cells in vivo would be to deplete mice of individual tumor sites and to determine if abnormal TCR ζ chain expression was related to lack of TIL effector function. Our studies T cell populations and determine which population, when show that TCR ζ expression is equivalent in both T cell depleted, inhibits the ability to reject tumors during conpopulations regardless of effector function. These data supcomitant tumor immunity. As for reasons stated above this is port the work of Levi and Srivastava in which they reported not currently feasible. that signaling abnormalities did not account for tumor-induced
The current study has investigated several areas of immune suppression (20) .
interest in tumor immunology. First, these data suggest that Since TCR ζ chain expression was similar in both T cell a decrease in TCR ζ chain expression was not responsible populations, we speculated that differences in V β expression for the inability of TIL to eradicate progressing tumors or their might account for the disparate effector function of TIL lack of cytolytic activity. Secondly, we have shown that the and TRL. However, analysis of freshly isolated TIL and TRL most predominant T cell clones present in progressing tumors revealed similar TCR V β usage in both populations. In order were also the most predominant clones present in rejected to determine if the enhanced cytotoxicity seen after in vitro tumor sites. Following secondary in vitro stimulation there was stimulation correlated with the expansion of TCR V β 1 and 8 no expansion of T cells bearing these TCR, yet an increase bearing T cells, which predominated in vivo, TCR V β usage in cytolytic function occurred. These data are reminiscent of was re-examined after MLTC. The data demonstrated that the Mackensen's study in which TCR V β 16 predominated freshly percent of T cells bearing these TCR V β decreased. Although analyzed TIL, yet a TCR V β 13 clone grew and responded to the number of TCR V β 1 and 8 bearing T cells decreased after the autologous tumor in vitro (2) . Further examination revealed the MLTC, this decrease may have been the result of an the TCR V β 13 clone was present in the freshly analyzed TIL increase in other TCR V β bearing T cells. However, there did sample, yet was not a predominantly used TCR V β . Collectively not appear to be a predominantly used TCR V β in either the Mackensen's study and the data presented here suggest that TIL or TRL population following in vitro stimulation. One the predominant TCR V β used by lymphocytes infiltrating explanation for this is that there may have been a loss of the regressing or rejected tumors may not represent the tumor-TCR V β 1 and 8 bearing T cells that were not capable of reactive T cells which grow in culture or respond to the responding to the tumor cells in vitro. If a population of TCR autologous tumor in vitro. V β 1 and 8 bearing T cells died in culture, then the remaining cells could appear more oligoclonal upon examination of their CDR3 regions. An examination of the CDR3 regions did
